Track topics on Twitter Track topics that are important to you
KOL Perspectives: Upadacitinib for Rheumatoid Arthritis
This KOL Insight briefing focuses on perceptions of novel upadacitinib data in RA.
The briefing includes analysis of KOL opinion on the following topic areas
Efficacy safety of upadacitinib in the SELECT COMPARE trial csDMARDIR patients
Efficacy safety of upadacitinib as a monotherapy in SELECT MONOTHERAPY trial MTXIR patients
Views on dose response for upadacitinib
Majority of KOLs had a positive opinion of upadacitinib's efficacy, particularly vs. adalimumab, in the SELECT COMPARE trial
Most KOLs had a favorable opinion of Week 12 upadacitinib data vs. adalimumab from the SELECT COMPARE trial
KOLs appeared unsure of upadacitinib's comparative efficacy vs. other JAK inhibitors, with many citing the need for headtohead studies.
The insight briefing is based on Sociable Pharma's analysis of primary research with our RA key opinion leaders KOLs
In total, we conducted interviews with 10 KOLs: Five Europebased five USbased
Interviews performed in Q2 2018
KOL data is analyzed to produce: Charts summarizing KOL opinions
Chart callouts of key information details
Summary of KOL reporting trends
Insight from Sociable Pharma's analysts.
Reasons to buy
Combines Qualitative semiquantitative insight from key opinion leaders on "Upadacitinib for Rheumatoid Arthritis"
Includes insight recommendations from our diseasespecific healthcare analysts
Utilizes independent expert viewpoints to validate the impact of new clinical data emerging trends on management of rheumatoid arthritis
Provides costeffective support for your advisory boards, with topics acting as a catalyst for further expert discussion.NEXT ARTICLE
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...